CMRC Children's Memorial Research Center
Oncology

For information on the following Clinical Trials, please contact the
Hematology, Oncology and Stem Cell Transplantation Department
at 773-880-4562 during 8:30 AM to 5:00 PM Central Standard Time.

  Acute Lymphoblastic Leukemia (ALL): Investigator
AALL0232 High Risk B-precursor Acute Lymphoblastic Leukemia Elaine Morgan, MD 
AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia Elaine Morgan, MD
AALL03B1 Classification of Acute Lymphoblastic Leukemia Elaine Morgan, MD
AALL0433 Intensive Treatment for Intermediate-risk Relapse of Childhood B-Precursor acute Lymphoblastic Leukemia (ALL); A Randomized Trial of Vincristine Strategies Elaine Morgan, MD 
AALL0434 Intensified Methotrexate, Nelarabine (Compound 506u78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia Elaine Morgan, MD
AALL05B1 A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens Elaine Morgan, MD
ERWINASE For Acute Lymphoblastic Leukemia (ALL) Treatment under IND 290 According to Erwinase Master Treatment Protocol Stanley Chaleff, MD
T2005-003 A Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia Nobuko Hijiya, MD
T2006-001 A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSB 374551) in Children with Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058 Nobuko Hijiya, MD
     
  Acute Myeloid Leukemia (AML): Investigator
AAML0431 The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the age of 4 Years Elaine Morgan, MD
AAML0523 A Phase I/II Study of CLOLAR (Clofarabine, IND# 73,789) in Combination with Cytarabine in Pediatric Patients with Refractory / Relapsed Leukemia Elaine Morgan, MD
AAML0531 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Elaine Morgan, MD
     
  Anaplastic Large Cell Lymphoma (ALCL): Investigator
ANHL0131 A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen Including Vinblastine Elaine Morgan, MD
     
  Developmental Therapeutics: Investigator
ADVL0319 Phase I Study of CC-5013 (Lenalidomide) in Pediatric Patients with Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome Stewart Goldman, MD
ADVL0413 A Phase I Study of Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (Bay 43-9006) in Children with Refractory Solid Tumors or Refractory Leukemias Stewart Goldman, MD
ADVL0414 A Phase I Study of Temozolomide, Oral Irinotecan and Vincristine for Children with Refractory Solid Tumors Stewart Goldman, MD
ADVL0416 A Phase 1 Study of SAHA in Pediatric Patients with Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Stewart Goldman, MD
ADVL04P2 A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia Stewart Goldman, MD
ADVL0515 A Phase I Study of Vinblastine in Combination with Carboplatin for Children with Newly Diagnosed and Recurrent Low-Grade Gliomas Stewart Goldman, MD
ADVL0516 A Phase I Study of BMS-354835 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia Stewart Goldman, MD
ADVL0517 A Phase I Study of Ispinesib (SB-715992) In Pediatric Patients with Relapsed or Refractory Solid Tumors Stewart Goldman, MD
ADVL0525 A Phase II Study of Pemetrexed in Children with Recurrent Malignancies David Walterhouse, MD
ADVL0714 A Phase I Study of VEGF Trap in Children with Refractory Solid Tumors Stewart Goldman, MD
     
  Ewings Sarcoma: Investigator
AEWS02B1 A Groupwide Biology and Banking Study for Ewing Sarcoma David Walterhouse, MD
AEWS07B1 A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens David Walterhouse, MD
AEWS0621 A Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults with Recurrent or Refractory Ewing Sarcoma David Walterhouse, MD
     
  Germ Cell: Investigator
AGCT0132 A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors Joanna Weinstein, MD
     
  Hepatoblastoma (HEP): Investigator
9346 Hepatoblastoma Biology Study and Tissue Bank Morris Kletzel, MD
AEPI04C1 Low Birth Weight & Other Risk Factors for Hepatoblastoma Yasmin Gosiengfiao, MD
     
  Hodgkins (HOD): Investigator
AHOD0031 A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Elaine Morgan, MD
AHOD03P1 Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD) Joanna Weinstein, MD 
AHOD0431 A Phase III Study for the treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease Joanna Weinstein, MD
AHOD0521 A Phase II Study of Bortezomib (Velcade, PS-341, IND #58433) in Combination with Ifosfamide / Vinorelbine in Pediatric Patients and Young Adults with Refractory / Recurrent Hodgkin Disease Yasmin Gosiengfiao, MD
     
  Late Effects: Investigator
ALTE03N1 Key Adverse Events after Childhood Cancer Reggie Duerst, MD
     
  LCH/HLH: Investigator
HLH-2004  Hemophagocytic Lymphohistiocytosis: Treatment Protocol of the Second International Study, HLH-2004 Elaine Morgan, MD
     
  Miscellaneous: Investigator
ANHL0221 A Phase II Study of the Combination of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults with CD20 Positive Post-Transplant Lymphoproliferative Disease (PTLD) following Solid Organ Transplantation (SOT) Elaine Morgan, MD
     
  Neuroblastoma (NBL): Investigator
ANBL0032 Phase III Randomized Study of Chimeric Antibody 14.18 in High Risk NBL following Myeloablative Therapy and Autologous Stem Cell Rescue Joanna Weinstein, MD
ANBL00B1 Neuroblastoma Biology Studies 		 Joanna Weinstein, MD
ANBL00P2 Perinatal Neuroblastoma: Expectant Observation. A COG Pilot Study Joanna Weinstein, MD
ANBL00P3 Use of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus Joanna Weinstein, MD
ANBL0421 Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma Joanna Weinstein, MD
ANBL0532 Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma Joanna Weinstein, MD
ANBL0621 A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent in Children with Relapsed or Refractory Neuroblastoma Joanna Weinstein, MD
ANBL00B1 Neuroblastoma Biology Studies Joanna Weinstein, MD
     
  Osteosarcoma (OST): Investigator
9851 Osteosarcoma Biology Protocol: Companion to Intergroup Therapeutic Studies David Walterhouse, MD
AOST0221 A Phase II Study of Aerosolized GM-CSF in Patients with First Pulmonary Recurrence of Osteosarcoma David Walterhouse, MD
AOST0331 Randomized Trial to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Therapy David Walterhouse, MD
     
  Rare Tumors (RAR): Investigator
ABTR01B1 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors David Walterhouse, MD
ARAR0331 Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy David Walterhouse, MD
ARAR0332 Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy Yasmin Gosiengfiao, MD
     
  Renal (REN): Investigator
9442 National Wilms' Tumor Late Effects Study Morris Kletzel, MD
AREN0321 Treatment of High Risk Renal Tumor Yasmin Gosiengfiao, MD
AREN03B2 Renal Tumors Classification, Biology and Banking Study Yasmin Gosiengfiao, MD
AREN0532 Treatment of Very Low, Low and Standard Risk Favorable Histology Wilms Tumor Yasmin Gosiengfiao, MD
AREN0533 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors Yasmin Gosiengfiao, MD
     
  Retinoblastoma (RET): Investigator
ARET0231 A Single Arm Trial of Systemic and Subtenon Chemotherapy for Groups C and D Intraocular Retinoblastoma Joanna Weinstein, MD
ARET0331 Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma Joanna Weinstein, MD
ARET0332 Study of Unilateral Retinoblastoma with and without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy Joanna Weinstein, MD
     
  Rhabdomyosarcoma (RST): Investigator
ARST0331 Low Risk Rhabdomyosarcoma (VAC with lower doses of cytoxan +/- RT) David Walterhouse, MD
ARST0332 Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas NRSTS David Walterhouse, MD
ARST0431 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma David Walterhouse, MD
ARST0531 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma David Walterhouse, MD
9902 A Group-Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens. An Intergroup Rhabdomyosarcoma Study Group Protocol David Walterhouse, MD